분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-05-15 15:19:22 , Hit : 2827
 Janssen's experimental drug for hepatitis C gets FDA fast track


Print Alexi Friedman/The Star-Ledger By Alexi Friedman/The Star-Ledger The Star-Ledger
Email the author | Follow on Twitter
on May 13, 2013 at 1:29 PM, updated May 13, 2013 at 3:06 PM
View/Post Comments
jansse.jpg
Janssen   Federal regulators have granted priority review for Janssen Research & Development’s experimental treatment for hepatitis C, a contagious liver disease that affects more than 3 million people in the United States.

Today, Raritan-based Janssen said the Food and Drug Administration gave the designation to its application for simeprevir, an investigational medicine taken as a once-a-day pill in combination with pegylated interferon and ribavirin.

The treatment is for adult patients with genotype 1 chronic hepatitis C, according to Janssen, a unit of New Brunswick-based Johnson & Johnson.

The FDA grants priority review to medicines that may offer major advances in care or provide a treatment option where no adequate therapy exists. The regulatory federal review process is likely to last no more than six months, with a decision expected by year's end, said Janssen spokesman Craig Stoltz. No pricing information was available.

Gaston Picchio, who is Janssen’s hepatitis disease area leader, called hepatitis C a “global epidemic,” and said in a statement the FDA’s designation is “a significant step forward in making this therapy available to physicians” and their patients.

Simeprevir, developed by Janssen and Swedish drug company Medivir AB, works by blocking the protease enzyme that allows the hepatitis C virus to replicate in host cells.

The submission for simeprevir followed data from clinical trials in which patients who had relapsed after having received interferon-based treatment were administered the Janssen drug.

The most common side effects reported were fatigue, itch and fever.


And check out our redesigned mobile site by visiting NJ.com from any mobile browser.

About 150 million people worldwide are infected with hepatitis C, and 350,000 people each year die from the disease, according to information on the World Health Organization web site.

The disease can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. The most common ways it can be transmitted is through contaminated blood transfusions and injections with contaminated syringes, the World Health Organization said.

Less common is transmission from sex with an infected person. The disease cannot be spread through breast milk, food or water, or casual contact such as kissing, and sharing food with an infected person, according to the website.







727   임자 있는 초원들쥐가 외간들쥐를 거들떠보지도 않는 이유: 후성유전학  이성욱 2013/06/05 3279
726   면역시스템이 유익세균과 평화로운 공존을 유지하는 방법  이성욱 2013/05/28 2492
725   TNF를 이용한 안전한 항종양 치료법  이성욱 2013/05/28 2656
724   Viruses in the gut protect from infection  이성욱 2013/05/22 2907
723   황우석을 넘어서: 미국의 과학자들, 체세포복제 기술로 인간 배아줄기세포 제조 성공  이성욱 2013/05/17 2462
  Janssen's experimental drug for hepatitis C gets FDA fast track  이성욱 2013/05/15 2827
721   세상을 바꿀 10가지 기술  이성욱 2013/05/13 2330
720   Most Europeans share recent ancestors  이성욱 2013/05/10 2156
719   약물 저항성 세균을 파괴하는 방법  이성욱 2013/05/10 2552
718   분자생물학의 거성(巨星) 떨어지다; 프랑수아 자콥의 삶과 업적  이성욱 2013/05/09 2833
717   FDA fast tracks AbbVie hepatitis C drug  이성욱 2013/05/08 2196
716   Targeted drugs to tackle hepatitis C  이성욱 2013/05/06 1798
715   DNA: Celebrate the unknowns  이성욱 2013/04/26 1972
714   Hepatitis C drug nears approval  이성욱 2013/04/24 2121
713   텔로머레이즈를 표적으로 삼는 새로운 항암 요법  이성욱 2013/04/24 3107
712   A pathogenic picornavirus acquires an envelope by hijacking cellular membranes  이성욱 2013/04/23 3003
711   BMS, Santaris Make Potentially $100M+ mRNA-Targeting Deal  이성욱 2013/04/17 2148
710   Scientists Map Elusive 3-D Structure of Telomerase Enzyme, Key Actor in Cancer, Aging  이성욱 2013/04/17 2305
709   Gilead seeks FDA OK for game-changing hepatitis C drug  이성욱 2013/04/10 2114
708   'RNA sponge' mechanism may cause ALS/FTD neurodegeneration  이성욱 2013/04/02 2605

[이전 10개] [1]..[21][22][23][24][25][26][27] 28 [29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN